Clarkston Capital Partners LLC Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Clarkston Capital Partners LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 31.1% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 57,777 shares of the biopharmaceutical company’s stock after buying an additional 13,700 shares during the period. Clarkston Capital Partners LLC’s holdings in Pfizer were worth $1,672,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Olistico Wealth LLC acquired a new stake in Pfizer during the 2nd quarter valued at approximately $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer during the second quarter worth approximately $29,000. Gladius Capital Management LP increased its stake in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares during the last quarter. Quarry LP acquired a new stake in Pfizer in the second quarter valued at $31,000. Finally, Financial Connections Group Inc. bought a new position in Pfizer during the 2nd quarter valued at $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of a number of recent analyst reports. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Citigroup started coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective on the stock. Finally, StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Stock Down 4.7 %

Shares of PFE stock opened at $24.80 on Monday. The stock has a market cap of $140.54 billion, a P/E ratio of 33.51, a price-to-earnings-growth ratio of 0.79 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a fifty day moving average price of $28.64 and a 200 day moving average price of $28.67. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter last year, the company earned ($0.17) EPS. Pfizer’s revenue was up 31.2% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.77%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is currently 227.03%.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.